The patient had been on Tysabri for 31 months (almost 3 years). Tysabri was not approved in the EU until Jul 2006. Most countries in the EU except Germany and the UK have long reimbursement application processes (6 months or longer). The UK has local reimbursement application processes. Therefore it is highly likely this latest case in the 4th PML case from a German patient.

As a US Tysabri patient, this sure makes me feel more confident that the TOUCH program is providing an extra measure of safety.